SEATTLE, Aug. 9, 2019 /PRNewswire/ — Bardy Diagnostics, Inc., (“BardyDx”), a leading provider of ambulatory cardiac monitoring technologies and custom data solutions, announced that HealthTech Arkansas, a healthcare accelerator and investment fund that connects early-stage healthcare companies with disruptive technologies to Arkansas healthcare providers, has selected BardyDx to participate in the organization’s 2019 accelerator program. BardyDx was chosen for its innovative advancements in cardiac monitoring by delivering industry-leading diagnostic accuracy with the Carnation Ambulatory Monitor (“CAM™”), the industry’s only P-wave centric™ ambulatory cardiac patch monitor and arrhythmia detection device.

• 

• 

HealthTech Arkansas is a new and expanded iteration of two previous accelerator programs in the state, Health InnovatAR and HubX-LifeSciences. This year, with more provider partners and increased investment for participating companies, HealthTech Arkansas is focused on bringing the most innovative healthcare technologies to Arkansas. The 2019 cohort selection was announced this week at the Arkansas Heart Hospital with a welcome from CEO Dr. Bruce Murphy, followed by a message from Arkansas Governor Asa Hutchinson and presentations from each of the six chosen companies. Both Dr. Murphy and Governor Hutchinson focused on the importance of working together to bring innovative technologies to Arkansas.

“It’s an honor to be selected as part of the 2019 accelerator cohort,” said Ken Nelson, BardyDx Chief Commercial Officer. “HealthTech Arkansas presents an invaluable opportunity to perform clinical studies with highly-engaged and pioneering healthcare organizations that are eager to implement the newest innovative technologies, like the CAM patch, to advance their clinical care – a clear win for both BardyDx and each partnering institution.”

This year’s six companies were selected from hundreds of applicants across 18 different countries. The cohort will participate in a program that provides them the opportunity to partner with and build solutions specifically identified by Arkansas Heart Hospital, Arkansas Children’s, Arkansas Urology, Baptist Health, CHI St. Vincent, Conway Regional, Mercy, the University of Arkansas for Medical Sciences (UAMS), and Washington Regional Medical Center as areas of opportunity within their organizations. Each of the cohort companies will receive seed investment as well as complete and total access to clinicians and administrators at each partnering site.

“We’re delighted to have the participation of BardyDx as one of six companies in our cohort this year,” said Jeff Stinson, Director of HealthTech Arkansas. “Collectively, they’re among the most accomplished early stage healthcare companies in the country. BardyDx was specifically chosen because the leadership teams in our partner hospitals believe the company can significantly increase the quality of care through its innovative devices. We can’t wait to begin our work with BardyDx.”

This distinction adds to the growing market recognition of the innovative P-wave centric CAM patch. Recently, BardyDx was named both the winner of the 2019 MedTech Breakthrough Award for Best New Diagnostic Technology and the winner of the 2019 Frost & Sullivan Award for Technology Innovation in Remote Cardiac Monitoring. Also, BardyDx was recently named the winner of the Impact Pediatric Health Competition hosted by the nation’s leading pediatric healthcare institutions at SXSW 2019 for the CAM’s unique pediatric-friendly design and potential to address significant unmet needs in pediatric healthcare. In addition, BardyDx was also selected as the winner of the 2018 Fierce Innovation Life Sciences Award for Medical Device Innovation from the leading industry publisher of FierceBiotech & FiercePharma.

About HealthTech Arkansas:

HealthTech Arkansas is a healthcare accelerator and investment fund that connects early stage healthcare companies bringing disruptive technologies to the market with Arkansas healthcare providers for the purpose of conducting pilot projects. We target the intersection of technology and healthcare in three categories: digital health (software), connected medical devices and diagnostic platforms. Our program is by providers and for providers, so we seek technologies that can improve our providers’ quality of care and increase their efficiency. Additional information can be found at www.healthtecharkansas.com.

About Bardy Diagnostics:

Bardy Diagnostics, Inc. is an innovator in digital health and remote patient monitoring, with a focus on providing the most diagnostically-accurate and patient-friendly cardiac patch monitors to the industry. The company’s CAM patch is a non-invasive, P-wave centric™ ambulatory cardiac monitor and arrhythmia detection device that is designed to improve patient compliance for adults and children through its lifestyle-enabling form factor. Designed to be worn comfortably and discreetly, the female-friendly, hourglass-shaped CAM patch is placed on the center of the chest, directly over the heart. The proprietary technology of the CAM patch provides optimal detection and clear recording of the often difficult-to-detect P-wave, the signal of the ECG waveform that is essential for accurate arrhythmia diagnosis and the determination of appropriate medical or procedural intervention. For more information, please visit www.bardydx.com.

MEDIA CONTACT:
Jonathan Wu
Director, Marketing
Bardy Diagnostics, Inc.
1-844-422-7393
jwu@bardydx.com

SOURCE Bardy Diagnostics, Inc.

Related Links
http://www.bardydx.com

SEATTLE, June 19, 2019 /PRNewswire/ — Bardy Diagnostics, Inc., (“BardyDx”), a leading provider of ambulatory cardiac monitoring technologies and custom data solutions, announced that MedTech Innovator, the premier nonprofit startup accelerator in the medical technology industry, has selected BardyDx to participate in the organization’s 2019 Showcase program, featuring the most promising medical technologies from around the globe. BardyDx was chosen for its innovative advancements in cardiac monitoring by delivering industry-leading diagnostic accuracy with the Carnation Ambulatory Monitor (“CAM™”), the industry’s only P-wave centric™ ambulatory cardiac patch monitor and arrhythmia detection device.

• 

• 

The program commences today in San Francisco, where the leadership teams from its 50 startups will gather for the annual MedTech Innovator Summit. During this two-day exclusive event, innovators from early to later-stage startups will collaborate with MedTech Innovator’s corporate partners to find solutions to common challenges and mechanisms to accelerate their technologies. All 50 companies will then present in a Showcase and partnering meetings with executives and investors on June 21 at the Wilson Sonsini Goodrich & Rosati’s 27th Annual Medical Device Conference in San Francisco. The program culminates September 23-25 in Boston, where all companies will present in Showcase panels and gain access to exclusive partnering and roundtables at The MedTech Conference, powered by AdvaMed.

“We are thrilled to be included in this distinguished cohort of innovating companies developing cutting-edge and disruptive technologies in MedTech,” said Ken Nelson, BardyDx Chief Commercial Officer. “We look forward to working with MedTech Innovator and receiving unparalleled visibility and invaluable access to its network of investors, providers, payers, and industry stakeholders through this highly selective program.”

From an initial applicant pool of over 800 applicants spanning 34 countries, BardyDx was chosen among 150 best-in-class medical device, diagnostic, and digital health companies to participate at one of the six regional qualifying MedTech Innovator Pitch Events held in March. BardyDx was selected as part of the 50 advancing innovators from the qualifying round to the Showcase program. 

“We take great pride in bringing the world’s best medtech ecosystem together with standout entrepreneurs to provide them with the resources and connections needed to bring their transformative technologies to patients,” said Paul Grand, CEO of MedTech Innovator.

This distinction adds to the growing market recognition of the innovative P-wave centric CAM patch. Recently, BardyDx was named both the winner of the 2019 MedTech Breakthrough Award for Best New Diagnostic Technology and the winner of the 2019 Frost & Sullivan Award for Technology Innovation in Remote Cardiac Monitoring. Also, BardyDx was recently named the winner of the Impact Pediatric Health Competition hosted by the nation’s leading pediatric healthcare institutions at SXSW 2019 for the CAM’s unique pediatric-friendly design and potential to address significant unmet needs in pediatric healthcare. In addition, BardyDx was also selected as the winner of the 2018 Fierce Innovation Life Sciences Award for Medical Device Innovation from the leading industry publisher of FierceBiotech & FiercePharma.

The full list of the 2019 MedTech Innovator Top 50 Showcase & Accelerator Companies can be found here. 

About MedTech Innovator:

MedTech Innovator is the medical technology industry’s nonprofit global competition and accelerator for innovative medical device, digital health, and diagnostic companies. Its mission is to improve the lives of patients by accelerating the growth of companies that are transforming the healthcare system. MedTech Innovator is the largest platform of its kind, providing participants with broad exposure and mentorship from the leading players in the MedTech industry. Additional information can be found at https://medtechinnovator.org/.

About Wilson Sonsini Goodrich & Rosati’s Medical Device Conference:

Wilson Sonsini Goodrich & Rosati, the premier provider of legal services to technology, life sciences, medical and growth enterprises worldwide, will host its 27th Annual Medical Device Conference on June 21. This year’s Conference will focus on understanding the challenges facing the MedTech start-up today, and the strategies that are emerging to respond to these challenges, presented by industry CEOs, venture capitalists, industry strategists, investment bankers, and market analysts. For more information, please visit https://mdc.wsgrevents.com.

About Bardy Diagnostics:

Bardy Diagnostics, Inc. is an innovator in digital health and remote patient monitoring, with a focus on providing the most diagnostically-accurate and patient-friendly cardiac patch monitors to the industry. The company’s CAM patch is a non-invasive, P-wave centric™ ambulatory cardiac monitor and arrhythmia detection device that is designed to improve patient compliance for adults and children through its lifestyle-enabling form factor. Designed to be worn comfortably and discreetly, the female-friendly, hourglass-shaped CAM patch is placed on the center of the chest, directly over the heart. The proprietary technology of the CAM patch provides optimal detection and clear recording of the often difficult-to-detect P-wave, the signal of the ECG waveform that is essential for accurate arrhythmia diagnosis and the determination of appropriate medical or procedural intervention. For more information, please visit www.bardydx.com.

MEDIA CONTACT:
Jonathan Wu
Director, Marketing
Bardy Diagnostics, Inc.
1-844-422-7393
jwu@bardydx.com

SOURCE Bardy Diagnostics, Inc.

Related Links:
http://www.bardydx.com

SEATTLE, June 6, 2019 /PRNewswire/ — Bardy Diagnostics, Inc., (“BardyDx”), a leading provider of ambulatory cardiac monitoring technologies and custom data solutions, announced that MedTech Breakthrough, an independent organization that recognizes the top companies and solutions in the global health and medical technology market, has recognized the Carnation Ambulatory Monitor (CAM™) with the “Best New Diagnostic Technology” award in the 2019 MedTech Breakthrough Awards program. BardyDx earned the distinction for its innovative P-wave centric™ ambulatory cardiac patch monitoring and arrhythmia detection technology.

• 

• 

Reliably detecting and recording the P-wave, a small amplitude signal of the ECG originating in the atrium, is essential to accurate arrhythmia diagnosis and the determination of appropriate medical or procedural intervention. By focusing on the detection and recording of the P-wave, BardyDx advances cardiac monitoring by delivering industry leading diagnostic accuracy.

“It is an honor to be recognized by the MedTech community as one of the innovating companies and technologies paving the way for the future of cardiac monitoring,” said Gust H. Bardy, MD, Founder and Chief Executive Officer of Bardy Diagnostics. “This award recognizes our collective drive at BardyDx towards transforming clinical care and developing an efficient, effective, and accurate healthcare solution that finally addresses the limitations and challenges of current cardiac monitors faced by clinical decision-makers day-in and day-out.”

The MedTech Breakthrough Awards program is the premier awards and recognition platform founded to recognize the medical and health technology innovators, leaders and visionaries from around the world. The program evaluates and recognizes break through solutions and companies in a range of categories, including Medical Devices, mHealth, Robotics, TeleHealth, Patient Engagement, Electronic Health Records (EHR), Healthcare Security, Medical Data and more. This year’s program attracted more than 3,500 nominations from over 15 different countries throughout the world that were evaluated by an independent panel of experts within the MedTech industry, with the winning products and companies selected based on a variety of considerations, including innovation, design and user-experience.

“BardyDx’s non-invasive P-wave centric CAM patch is disrupting decades of old practice and technology for cardiac diagnostics and monitoring,” said James Johnson, managing director, MedTech Breakthrough. “CAM represents a true digital health breakthrough and we are thrilled to recognize the Company with a 2019 MedTech Breakthrough Award in recognition of their outstanding success and innovation in the digital health space.”

This award adds to the growing market recognition of the innovative P-wave centric CAM patch. Last month, BardyDx was named both the winner of the 2019 Frost & Sullivan Award for Technology Innovation in Remote Cardiac Monitoring and the winner of the 2019 GeekWire Award in the Hardware of the Year category. Also, BardyDx was recently named the winner of the Impact Pediatric Health Competition hosted by the nation’s leading pediatric healthcare institutions at SXSW 2019 for the CAM’s unique pediatric-friendly design and potential to address significant unmet needs in pediatric healthcare. In addition, BardyDx was also selected as the winner of the 2018 Fierce Innovation Life Sciences Award for Medical Device Innovation from the leading industry publisher of FierceBiotech & FiercePharma.

The full list of the 2019 MedTech Breakthrough Award winners can be found here. 

About MedTech Breakthrough:

Part of Tech Breakthrough, a leading market intelligence and recognition platform for global technology innovation and leadership, the MedTech Breakthrough Awards program is an independent program devoted to honoring excellence in medical and health related technology companies, products, services and people. The MedTech Breakthrough Awards provide a platform for public recognition around the achievements of breakthrough health and medical companies and products in categories that include Patient Engagement, mHealth, Health & Fitness, Clinical Administration, Healthcare IoT, Medical Data, Healthcare Cybersecurity and more. For more information visit MedTechBreakthrough.com.  

About Bardy Diagnostics:

Bardy Diagnostics, Inc. is an innovator in digital health and remote patient monitoring, with a focus on providing the most diagnostically-accurate and patient-friendly cardiac patch monitors to the industry. The company’s CAM patch is a non-invasive, P-wave centric™ ambulatory cardiac monitor and arrhythmia detection device that is designed to improve patient compliance for adults and children through its lifestyle-enabling design. Designed to be worn comfortably and discreetly, the female-friendly, hourglass-shaped CAM patch is placed on the center of the chest, directly over the heart for optimum ECG signal collection. The proprietary technology of the CAM patch provides optimal detection and clear recording of the often difficult-to-detect P-wave, the signal of the ECG waveform that is essential for accurate arrhythmia diagnosis. For more information, please visit www.bardydx.com.

MEDIA CONTACT:
Jonathan Wu
Director, Marketing
Bardy Diagnostics, Inc.
1-844-422-7393
jwu@bardydx.com

SOURCE Bardy Diagnostics, Inc.

Related Links
http://www.bardydx.com

CAM™’s unique P-wave-centric ECG monitor offers unmatched signal clarity and superior arrhythmia detection

SANTA CLARA, Calif., May 6, 2019 /PRNewswire/ — Based on its recent analysis of the North American remote cardiac monitoring market, Frost & Sullivan recognizes Bardy Diagnostics, Inc. (BardyDx) with the 2019 North America Technology Innovation Award for its Carnation Ambulatory Monitor™ (CAM™) patch. The CAM™ patch is a first-of-its-kind P-wave-centric surface electrocardiograph (ECG) arrhythmia detection device that leverages state-of-the-art engineering and design to deliver groundbreaking monitoring.

“The patch’s use of advanced engineering and design allows it to detect different arrhythmias occurring at the same time, positively impacting patient management, especially when the arrhythmias may require different treatment decisions. For example, the CAM™ patch can accurately detect classic atrial flutter (AFL) and paroxysmal atrial fibrillation (PAF) occurrences. With a typical monitor, AFL may be obscured by AF presence, resulting in inadequate treatments and increased costs and risks to the patient,” said Kamaljit Behera, Industry Analyst at Frost & Sullivan. “BardyDX developed the CAM™ patch to provide optimal detection and clear recording of the often difficult to detect P-wave, the signal of the ECG waveform that is essential for accurate arrhythmia diagnosis and subsequent patient management.”

The CAM™ patch’s novel circuit design and signal capture technologies result in accurate and clear P-wave detection and recording. As a result, the CAM™ patch delivers improved ECG resolution and diagnostic accuracy while simultaneously providing continuous data on the heart’s rhythm.

In addition, CAM™ patch’s ease-of-use promotes patient compliance and streamlines clinical workflows. To simplify diagnostics and reporting further, BDxCONNECT, a companion patient management portal, provides healthcare professionals with a single system for creating, accessing, and managing patient CAM™ reports. Finally, BardyDx’s augmented intelligence and visualization technologies will accelerate information delivery and clinically meaningful insights to clinicians while enhancing operational efficiencies.

“These product benefits have earned the company a wide interest from investors, including some of the largest healthcare venture capital firms, and many of the top US health systems are already using the CAM™ patch. Furthermore, the device is one of only a few monitors suitable for pediatric applications,” noted Behera. “Overall, BardyDx’s thought leadership, unparalleled innovation, and disruptive potential have positioned it for greater adoption in the cardiac monitoring market.”

Each year, Frost & Sullivan presents this award to the company that develops a product with innovative features and functionality that is gaining rapid acceptance in the market. The award recognizes the quality of the solution and the customer value enhancements it enables.

Frost & Sullivan Best Practices awards recognize companies in a variety of regional and global markets for demonstrating outstanding achievement and superior performance in areas such as leadership, technological innovation, customer service, and strategic product development. Industry analysts compare market participants and measure performance through in-depth interviews, analysis, and extensive secondary research to identify best practices in the industry.

About Bardy Diagnostics, Inc.
Bardy Diagnostics, Inc. is an innovator in digital health and remote patient monitoring, with a focus on providing the most diagnostically-accurate and patient-friendly cardiac monitors to the industry. The company’s CAM patch is a non-invasive, P-wave centric™ ambulatory cardiac monitor and arrhythmia detection device that is designed to improve patient compliance for adults and children weighing more than 10kg (22lbs) through its lifestyle-enabling design. Designed to be worn comfortably and discreetly, the female-friendly, hourglass-shaped CAM patch is placed on the center of the chest, directly over the heart for optimum ECG signal collection. For more information, please visit www.bardydx.com.

About Frost & Sullivan
Frost & Sullivan, the Growth Partnership Company, works in collaboration with clients to leverage visionary innovation that addresses the global challenges and related growth opportunities that will make or break today’s market participants. For more than 50 years, we have been developing growth strategies for the global 1000, emerging businesses, the public sector, and the investment community. Contact us: Start the discussion.

Contact:
Bianca Torres
P: 1.210.477.8418
E: bianca.torres@frost.com

SOURCE Frost & Sullivan

Related Links
http://www.frost.com

SEATTLE, April 16, 2019 /PRNewswire/ — Bardy Diagnostics, Inc., (“BardyDx”), a leading provider of ambulatory cardiac monitoring technologies and custom data solutions, announced today it has raised $35.5 million in Series B funding, led by River Cities Capital Funds with participation from new investors HealthQuest Capital, Aperture Venture Partners, Aphelion Capital, Lumira Ventures, and Rex Health Ventures. Existing equity investors, SV Health Investors, Health Enterprise Partners, and Ascension Ventures also joined the round. The funds will be used to further accelerate growth of its innovative P-wave focused cardiac monitoring platform through expansion of BardyDx’s sales force and monitoring services, and to support advanced development programs, including augmented intelligence and visualization technologies.

“The caliber of our new investors in addition to our exceptional existing syndicate of financiers underscores the exciting opportunity before us,” said Gust H. Bardy, MD, Founder and Chief Executive Officer of BardyDx. “With these funds, we will grow our business by refining and expanding our primary goal of revealing to patients, and their physicians, the full complexity and meaning of their cardiac rhythm.” 

BardyDx’s Carnation Ambulatory Monitor (“CAM™”) is the industry’s only P-wave centric™ ambulatory cardiac patch monitor and arrhythmia detection device. The genesis of the CAM is a result of Dr. Bardy’s frustrations with the fundamental flaws rooted in the development and evolution of cardiac monitoring.

“For nearly 60 years, standard ECG engineering practices have over-processed the heart’s electrical message to make machines’ ‘lives’ easier at the expense of losing details in the ECG,” added Dr. Bardy. “In essence, such legacy engineering doesn’t listen to what the heart is trying to tell us but rather tells the heart what we are willing to hear. At BardyDx, our pioneering technology focuses on revealing the cardiac rhythm message fully, and in so doing, allows for precise and meaningful patient management predicated on cardiac truth.” 

BardyDx’s footprint within the cardiac monitoring industry continues to expand with growing recognition of the innovative P-wave centric technology. The company was recently selected winner of the Impact Pediatric Health Competition at SXSW, Children’s National Health System Pediatric Medical Device Innovation Competition, and 2018 Fierce Innovation Life Sciences Award for Medical Device Innovation. “Our Series B capital will continue to fuel the technological innovation that Dr. Bardy has always insisted on and for which BardyDx has come to be known,” said Mark Handfelt, BardyDx’s Chief Operating Officer.

BardyDx also announced that Rik Vandevenne, Managing Director of River Cities Capital Funds, and Garheng Kong, Managing Director of HealthQuest Capital, will join the company’s board of directors.

“It’s not every day you have the opportunity to partner with such a groundbreaking serial entrepreneur and innovator as Dr. Gust Bardy and the team at BardyDx,” said Vandevenne. “The company has a clear focus on putting the patient first and they have developed a clinically-superior ECG platform that is revolutionizing heart monitoring. We are excited for the opportunity to help further drive growth for the company while positively impacting the lives of thousands of people every week.”

About Bardy Diagnostics:

Bardy Diagnostics, Inc. is an innovator in digital health and remote patient monitoring, with a focus on providing the most diagnostically-accurate and patient-friendly cardiac patch and other monitors to the industry. The company’s CAM patch is a non-invasive, P-wave centric™ ambulatory cardiac monitor and arrhythmia detection device that is designed to improve patient compliance for adults and children weighing more than 10kg (22lbs) through its lifestyle-enabling design. Designed to be worn comfortably and discreetly, the female-friendly, hourglass-shaped CAM patch is placed on the center of the chest, directly over the heart for optimum ECG signal collection. The proprietary technology of the CAM patch provides optimal detection and clear recording of the often difficult-to-detect P-wave, the signal of the ECG waveform that is essential for accurate arrhythmia diagnosis. For more information, please visit www.bardydx.com.

About River Cities Capital Funds:

River Cities is a growth equity firm investing in high-potential healthcare and information technology companies. A consistent, cohesive team has honed its strategy over six funds with compelling performance. River Cities seeks to be a business partner first and a capital provider second, investing significant human capital to leverage its domain expertise and a network of thought leaders assembled over the last 25 years. With $750 million of capital raised and a consistent track record of success, River Cities has established itself as a preferred source of growth capital. The firm, located in Cincinnati, OH and Raleigh, NC, is actively seeking new investments for its Fund VI. For more information, please visit www.rccf.com.

MEDIA CONTACT:
Jonathan Wu
Director, Marketing
Bardy Diagnostics, Inc.
1-844-422-7393
jwu@bardydx.com

SOURCE Bardy Diagnostics, Inc.

Related Links
http://www.bardydx.com

SEATTLE, March 26, 2019 /PRNewswire/ — Bardy Diagnostics, Inc., (“BardyDx”), a leading provider of ambulatory cardiac monitoring technologies and custom data solutions, including the Carnation Ambulatory Monitor (“CAM™”), the industry’s first P-wave centric™ ambulatory cardiac patch monitor and arrhythmia detection device, announced it has been selected as one of four winners of the Impact Pediatric Health Competition held at SXSW 2019 hosted by the nation’s leading pediatric healthcare institutions across the US, including Children’s Healthcare of Atlanta, Boston Children’s Hospital, Cincinnati Children’s Hospital, Children’s Hospital Los Angeles, Seattle Children’s Hospital, Stanford Children’s Health, and Texas Children’s Hospital.

“It was an exciting opportunity to take part in the Impact Pediatric Health competition and present alongside an inspiring group of industry-disrupting innovators,” said Ken Nelson, BardyDx Chief Commercial Officer. “Being chosen amongst our peers to receive this award is an extraordinary honor and further fuels our corporate commitment to make a meaningful impact in pediatric care.”

The competition invites early stage companies representing the best in pediatric healthcare innovation to present how their products address the unique challenges of this younger patient population. From a pool of 50 applicants, BardyDx earned one of the twelve finalist spots to pitch to a distinguished judging panel of venture capitalists, industry leaders, and leading pediatric hospital representatives. BardyDx was ultimately chosen to receive a $25,000 prize provided by the Southwest National Pediatric Device Consortium (SWPDC) based on the CAM patch’s pediatric-friendly design and potential to improve the safety and delivery of pediatric care through its innovative P-wave centric technology.

“We were blown away by the level of talent and incredible innovation showcased at this year’s Impact Pediatric Health pitch competition,” said Chester Koh, MD, Executive Director of SWPDC. “At Impact Pediatric Health and SWPDC, we are always looking for the next cutting-edge breakthrough in the world of medical devices, and we are excited to stand beside these four companies and help accelerate the next generation of medical device companies impacting our youngest of patients.”

This award builds upon the growing market recognition of the innovative P-wave centric CAM patch for the pediatric patient population. Recently, BardyDx was also named winner of the Children’s National Health System Pediatric Medical Device Innovation Competition for the CAM’s unique pediatric-friendly design and potential to address significant unmet needs in pediatric healthcare. In addition, BardyDx was selected as the winner of the 2018 Fierce Innovation Life Sciences Award for Medical Device Innovation from the leading industry publisher of FierceBiotech & FiercePharma.

BardyDx and the list of Impact Pediatric Health winners can be found in the official announcement.

About Impact Pediatric Health:

Now in its fifth year, Impact Pediatric Health hosts an annual competition held at SXSW dedicated to showcasing and supporting innovative next generation pediatric healthcare companies focused on digital health and medical devices. Impact Pediatric Health was formed as a collaboration between seven of the largest and top-ranked (according to US News & World Report) children’s hospitals in the US. Additional information can be found at https://impactpediatric.health/.

About SXSW:

The South by Southwest (SXSW) Conference & Festivals celebrate the convergence of the interactive, film, and music industries. Fostering creative and professional growth alike, SXSW has become the premier destination for discovery and events featuring sessions, showcases, screenings, exhibitions, and a variety of networking opportunities. The Health Track at SXSW focuses on innovations that build and support the ecosystem of patients, providers, payers, policy makers, designers, entrepreneurs, and investors to improve outcomes in health and healthcare. Additional information can be found at www.sxsw.com.   

About Bardy Diagnostics:

Bardy Diagnostics, Inc. is an innovator in digital health and remote patient monitoring, with a focus on providing diagnostically-accurate and patient-friendly cardiac patch and other monitors to the industry. The company’s CAM patch is a non-invasive, P-wave centric™ ambulatory cardiac monitor and arrhythmia detection device that is designed to improve patient compliance for adults and children through its lifestyle-enabling design. Designed to be worn comfortably and discreetly, the female-friendly, hourglass-shaped CAM patch is placed on the center of the chest, directly over the heart for optimum ECG signal collection. The proprietary technology of the CAM patch provides optimal detection and clear recording of the often difficult-to-detect P-wave, the signal of the ECG waveform that is essential for accurate arrhythmia diagnosis. Additional information can be found at the recently launched redesign of the BardyDx corporate website at www.bardydx.com.

MEDIA CONTACT:
Jonathan Wu
Director, Marketing
Bardy Diagnostics, Inc.
1-844-422-7393
jwu@bardydx.com

SOURCE Bardy Diagnostics, Inc.

Related Links
http://www.bardydx.com

SEATTLE, March 6, 2019 /PRNewswire/ — Bardy Diagnostics, Inc., (“BardyDx”), a leading provider of ambulatory cardiac monitoring technologies and custom data solutions, including the Carnation Ambulatory Monitor (“CAM™”), the industry’s first P-wave centric™ ambulatory cardiac patch monitor and arrhythmia detection device, announced it has been selected as a finalist in the fifth annual Impact Pediatric Health Competition to be held at SXSW 2019 on March 8^th. Hosted by the nation’s leading pediatric healthcare institutions across the US, the competition invites early stage companies representing the best in pediatric healthcare innovation to present how their products address the unique challenges of this younger patient population.

“It’s an honor to be chosen as a finalist amongst such a talented pool of innovative technologies, all aimed at improving the lives of children,” said Gust H Bardy, MD, Bardy Diagnostics Founder and Chief Executive Officer. “With our products currently used in children’s hospitals across the country, BardyDx is excited for the opportunity to collaborate with the host pediatric healthcare institutions to further advance the CAM patch to meet the unique needs of children and become the standard of care for pediatric ambulatory cardiac monitoring.”

BardyDx earned one of the twelve finalist spots to pitch to a distinguished judging panel of venture capitalists, industry leaders, and leading pediatric hospital representatives. Additionally, the Southwest National Pediatric Device Consortium (SWPDC), anchored by Texas Children’s Hospital and Baylor College of Medicine, is providing up to $25,000 per awardee to accelerate devices designed to improve the safety and delivery of pediatric care.

“Impact Pediatric Health’s reputation for bringing together the leaders in pediatric medical technology innovations makes it the perfect venue to help identify and accelerate the next generation of medical device companies impacting our youngest of patients,” said Chester Koh, MD, SWPDC founder and lead principal investigator.

BardyDx and the list of Impact Pediatric Health finalists can be found at https://impactpediatric.health/.

BardyDx Advances in MedTech Innovator Competition

BardyDx also announced today that it was selected to advance to the qualifying round in the MedTech Innovator Competition from a pool of 750 applicants. BardyDx presented earlier this week at the MedTech Innovator Los Angeles Pitch Event, one of the six regional invitation events held over the next few months featuring a total of 150 best-in-class medical device, diagnostic, and digital health companies. Fifty companies will be selected from the MedTech Innovator Pitch round to the Showcase program, which prominently features the most innovative companies from around the world each year at two leading industry conferences: WSGR Medical Device Conference in June and The MedTech Innovator Showcase program at The MedTech Conference, powered by AdvaMed, in September.

About Impact Pediatric Health:

Now in its fifth year, Impact Pediatric Health hosts an annual competition held at SXSW dedicated to showcasing and supporting innovative next generation pediatric healthcare companies focused on digital health and medical devices. Impact Pediatric Health was formed as a collaboration between seven of the largest and top-ranked (according to US News & World Report) children’s hospitals in the US, including Children’s Healthcare of Atlanta, Boston Children’s Hospital, Cincinnati Children’s Hospital, Children’s Hospital Los Angeles, Seattle Children’s Hospital, Stanford Children’s Health, and Texas Children’s Hospital. Additional information can be found at https://impactpediatric.health/.

About SXSW:

The South by Southwest (SXSW) Conference & Festivals celebrate the convergence of the interactive, film, and music industries. Fostering creative and professional growth alike, SXSW has become the premier destination for discovery and events featuring sessions, showcases, screenings, exhibitions, and a variety of networking opportunities. The Health Track at SXSW focuses on innovations that build and support the ecosystem of patients, providers, payers, policy makers, designers, entrepreneurs, and investors to improve outcomes in health and healthcare. SXSW 2019 will take place March 8-17, 2019. Additional information can be found at www.sxsw.com.  

About MedTech Innovator:

MedTech Innovator is the medical technology industry’s nonprofit global competition and accelerator for innovative medical device, digital health, and diagnostic companies. Its mission is to improve the lives of patients by accelerating the growth of companies that are transforming the healthcare system. MedTech Innovator is the largest platform of its kind, providing participants with broad exposure and mentorship from the leading players in the medtech industry. Additional information can be found at https://medtechinnovator.org/.

About Bardy Diagnostics:

Bardy Diagnostics, Inc. is an innovator in digital health and remote patient monitoring, with a focus on providing diagnostically-accurate and patient-friendly cardiac patch and other monitors to the industry. The company’s CAM patch is a non-invasive, P-wave centric™ ambulatory cardiac monitor and arrhythmia detection device that is designed to improve patient compliance for adults and children through its lifestyle-enabling design. Designed to be worn comfortably and discreetly, the female-friendly, hourglass-shaped CAM patch is placed on the center of the chest, directly over the heart for optimum ECG signal collection. The proprietary technology of the CAM patch provides optimal detection and clear recording of the often difficult-to-detect P-wave, the signal of the ECG waveform that is essential for accurate arrhythmia diagnosis. Additional information can be found at the recently launched redesign of the BardyDx corporate website at www.bardydx.com.

MEDIA CONTACT:
Jonathan Wu
Director, Marketing
Bardy Diagnostics, Inc.
1-844-422-7393
jwu@bardydx.com

SOURCE Bardy Diagnostics, Inc.

Related Links
http://www.bardydx.com

SEATTLE, Feb. 28, 2019 /PRNewswire/ — Bardy Diagnostics, Inc., (“BardyDx”), a leading provider of ambulatory cardiac monitoring technologies and custom data solutions, announced today it has entered into a distribution agreement with JNC Medical, a distributor of innovative medical technologies based in Ottawa, Ontario. The agreement grants JNC Medical the right to distribute the BardyDx Carnation Ambulatory Monitor (“CAM™”), the industry’s first P-wave centric™ ambulatory cardiac patch monitor and arrhythmia detection device, in the Canadian market.

“The collaboration with JNC Medical strengthens BardyDx’s international distribution and business development initiatives, which are key priorities for the Company this year,” said Ken Nelson, BardyDx Chief Commercial Officer. “Combining BardyDx’s innovation and leadership in ambulatory cardiac monitoring with JNC Medical’s Canadian market-specific expertise, distribution logistics, and deep connections with Canadian physicians will accelerate penetration of the CAM patch into the global market.”

Following strong product demand in the US, the partnership aims to enable access to the CAM patch for all Canadian patients and accelerate the transition away from legacy Holter technologies and outdated ECG reporting solutions. As part of its distribution strategy, JNC Medical intends to leverage its healthcare industry networks and physician demands for extended monitoring, encouraging a transition to digital monitoring technologies.

“We are excited to partner with BardyDx by assisting in the commercialization of the market-disrupting CAM patch in Canada,” said JNC Medical Business Partner Christopher Mulvanny. “It is our goal to bring the world’s most innovative device technologies to Canadian physicians and patients, and the CAM patch is a perfect match to add to our growing portfolio.”

In preparation, BardyDx recently received a Health Canada Medical Device License, allowing the CAM patch to be marketed in Canada. Additionally, to support international expansion initiatives and as a compulsory requirement for entering the Canadian market, BardyDx was recently awarded MDSAP (Medical Device Single Audit Program) certification, a program involving a single regulatory audit of a medical device manufacturer’s quality management system that satisfies the requirements of multiple regulatory jurisdictions worldwide.

“Obtaining Health Canada’s approval for the CAM patch is an important milestone for us,” said Mark Handfelt, BardyDx Chief Operating Officer. “It is additional validation of our technology and quality programs and a vital step in laying the groundwork needed to provide BardyDx’s transformative ECG monitoring technologies to patients all over the world.”

About Bardy Diagnostics:
Bardy Diagnostics, Inc. is an innovator in digital health and remote patient monitoring, with a focus on providing diagnostically-accurate and patient-friendly cardiac patch and other monitors to the industry. The company’s CAM patch is a non-invasive, P-wave centric™ ambulatory cardiac monitor and arrhythmia detection device that is designed to improve patient compliance for adults and children weighing >10kg (22lbs) through its lifestyle-enabling design. Designed to be worn comfortably and discreetly, the female-friendly, hourglass-shaped CAM patch is placed on the center of the chest, directly over the heart for optimum ECG signal collection. The proprietary technology of the CAM patch provides optimal detection and clear recording of the often difficult-to-detect P-wave, the signal of the ECG waveform that is essential for accurate arrhythmia diagnosis. Additional information can be found at the recently launched redesign of the BardyDx corporate website at www.bardydx.com.

MEDIA CONTACT:
Jonathan Wu
Director, Marketing
Bardy Diagnostics, Inc.
1-844-422-7393
jwu@bardydx.com

SOURCE Bardy Diagnostics, Inc.

Related Links
http://www.bardydx.com

SEATTLE, Jan. 7, 2019 /PRNewswire/ — Bardy Diagnostics, Inc., (“BardyDx”), a leading provider of ambulatory cardiac monitoring technologies and custom data solutions, announced today it has achieved a significant year-end milestone of monitoring over 40,000 patients driven by rapid adoption of the Carnation Ambulatory Monitor (“CAM™”), the world’s first P-wave centric™ ambulatory cardiac patch monitor and arrhythmia detection device.

“Product acceptance continues to rapidly grow, supported by the positive customer reception to the CAM’s unique P-wave centric technology,” said Ken Nelson, Chief Commercial Officer. “With over 40,000 patients to date having benefited from the CAM patch, it is evident to our customers that P-wave specificity is essential for accurately diagnosing arrhythmias and determining appropriate medical or procedural intervention.”

The significance of the CAM patch’s P-wave focused clinical value was recently highlighted in the September 2018 issue of the American Heart Journal that published the results of a head-to-head comparison with the iRhythm Zio® XT patch. The study, “Comparison of two ambulatory patch ECG monitors: The benefit of the P-wave and signal clarity,” concluded that the BardyDx CAM patch identified 40% more arrhythmias and resulted in better, more informed clinical decision-making in 41% of patients over the iRhythm Zio® XT patch. In addition, an abstract presented at the 2018 American Heart Association Scientific Sessions in November titled, “P-Wave Centric Patch Monitors May Reduce Need for Implantable Monitors Following Cryptogenic Stroke,” suggested that the P-wave centric CAM patch should be used first to detect atrial fibrillation in cryptogenic stroke patients before the decision to implant an implantable loop recorder (ILR).

“Customers are voicing their excitement about finally having access to a diagnostic tool that is able to accurately and precisely identify arrhythmia type,” said BardyDx Founder and Chief Executive Officer, Gust H Bardy, MD. “We are excited to surpass this noteworthy record and look forward to impacting even more patient lives with our pioneering technology.”

The milestone builds upon the growing market recognition of the innovative P-wave centric features of the CAM patch. Most recently, BardyDx was selected as the winner of the 2018 Fierce Innovation Life Sciences Award for Medical Device Innovation from the leading industry publisher of FierceBiotech & FiercePharma and was also named winner of the Children’s National Health System Pediatric Medical Device Innovation Competition for the CAM’s unique pediatric-friendly design and potential to address significant unmet needs in pediatric healthcare. In addition, BardyDx was recently awarded an Innovative Technology contract with Vizient, Inc. upon recommendation of its member-led council of hospital experts for the CAM patch’s ability to enhance clinical care and patient safety.

About Bardy Diagnostics:

Bardy Diagnostics, Inc. is an innovator in digital health and remote patient monitoring, with a focus on providing diagnostically-accurate and patient-friendly cardiac patch and other monitors to the industry. The company’s CAM patch is a non-invasive, P-wave centric™ ambulatory cardiac monitor and arrhythmia detection device that is designed to improve patient compliance for adults and children through its lifestyle-enabling design. Designed to be worn comfortably and discreetly, the female-friendly, hourglass-shaped CAM patch is placed on the center of the chest, directly over the heart for optimum ECG signal collection. The proprietary technology of the CAM patch provides optimal detection and clear recording of the often difficult-to-detect P-wave, the signal of the ECG waveform that is essential for accurate arrhythmia diagnosis. Additional information can be found at the recently launched redesign of the BardyDx corporate website at www.bardydx.com.

MEDIA CONTACT:
Jonathan Wu
Director, Marketing
Bardy Diagnostics, Inc.
1-844-422-7393
jwu@bardydx.com

SOURCE Bardy Diagnostics, Inc.

Related Links
http://www.bardydx.com

SEATTLE, Dec. 17, 2018 /PRNewswire/ — Bardy Diagnostics, Inc., (“BardyDx”), a leading provider of ambulatory cardiac monitoring technologies and custom data solutions, announced today that it has been selected as a winner in the sixth annual Fierce Innovation Awards: Life Sciences Edition, an awards program from the leading industry publisher of FierceBiotech and FiercePharma aimed at identifying and showcasing outstanding innovations driving improvements and transformation in the digital health, biotech, and pharma industries. BardyDx earned top honors for the Carnation Ambulatory Monitor (“CAM™”), the world’s first P-wave centric™ ambulatory cardiac patch monitor and arrhythmia detection device.

“BardyDx is honored to be recognized for this prestigious distinction. Innovation is the core of our business, and it drives our vision to be the leading cardiac monitoring solutions provider in the industry,” said Gust H. Bardy, MD, BardyDx Founder and Chief Executive Officer. “By addressing the diagnostic shortcomings our clinicians and patients face day-in and day-out, our teams are inspired to deliver revolutionizing solutions like the P-wave focused CAM patch.”

Fierce Innovation Award applicants were evaluated on the merits of their product’s effectiveness, technical innovation, competitive advantage, financial impact, and true innovation. From this year’s strong talent pool, BardyDx was selected among three finalists in the Medical Device Innovation category by a distinguished judging panel of industry leaders for the CAM patch’s potential to profoundly impact patient care. 

“Our expert panel of judges reviewed hundreds of applications to find the best of the best,” said Rebecca Willumson, Publisher of FierceBiotech and FiercePharma. “We look for and found cutting edge organizations that have or are in the process of launching new technologies and services that are reinventing what it means to be a part of life sciences.”

The acceptance of this award builds upon the growing market recognition of the innovative P-wave centric features of the CAM patch. Most recently, BardyDx was selected as the winner of the Children’s National Health System Pediatric Medical Device Innovation Competition for the CAM’s unique pediatric-friendly design and potential to address significant unmet needs in pediatric healthcare. In addition, BardyDx was recently awarded an Innovative Technology contract with Vizient, Inc. upon recommendation of its member-led council of hospital experts for the CAM patch’s ability to enhance clinical care and patient safety.

BardyDx and the full list of featured winners can be found in the 2018 Fierce Innovation Report: Life Sciences Edition.

About Bardy Diagnostics:

Bardy Diagnostics, Inc. is an innovator in digital health and remote patient monitoring, with a focus on providing diagnostically-accurate and patient-friendly cardiac patch and other monitors to the industry. The company’s CAM patch is a non-invasive, P-wave centric™ ambulatory cardiac monitor and arrhythmia detection device that is designed to improve patient compliance for adults and children through its lifestyle-enabling design. Designed to be worn comfortably and discreetly, the female-friendly, hourglass-shaped CAM patch is placed on the center of the chest, directly over the heart for optimum ECG signal collection. The proprietary technology of the CAM patch provides optimal detection and clear recording of the often difficult-to-detect P-wave, the signal of the ECG waveform that is essential for accurate arrhythmia diagnosis. Additional information can be found at the recently launched redesign of the BardyDx corporate website at www.bardydx.com.

MEDIA CONTACT:
Jonathan Wu
Director, Marketing
Bardy Diagnostics, Inc.
1-844-422-7393
jwu@bardydx.com

SOURCE Bardy Diagnostics, Inc.

Related Links
http://www.bardydx.com